-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-033 in Chemotherapy Effects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-033 in Chemotherapy Effects report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MaaT-033 in Chemotherapy Effects Drug Details: MaaT-033 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-033 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-033 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MaaT-033 in Amyotrophic Lateral Sclerosis Drug Details: MaaT-033 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-013 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-013 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MaaT-013 in Metastatic Melanoma Drug Details:MaaT-013 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-013 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-013 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MaaT-013 in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZB-131 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZB-131 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZB-131 in Metastatic Pancreatic Cancer Drug Details: ZB-131 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Neratinib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neratinib in Pancreatic Cancer Drug Details: Neratinib (Nerlynx) is a member...
-
Product Insights
Hematopoietic Stem Cell Transplantation – Drugs In Development, 2023
Global Markets Direct’s, ‘Hematopoietic Stem Cell Transplantation - Drugs In Development, 2023’, provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Graft Versus Host Disease (GVHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Drugs In Development, 2023’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...